Synergic stimulation of serotonin 5-HT1A receptor and &#945;2-adrenoceptors for neuropathic pain relief: Preclinical effects of 2-substituted imidazoline derivatives by Di Cesare Mannelli, L et al.
Contents lists available at ScienceDirect
European Journal of Pharmacology
journal homepage: www.elsevier.com/locate/ejphar
Neuropharmacology and analgesia
Synergic stimulation of serotonin 5-HT1A receptor and α2-adrenoceptors for
neuropathic pain relief: Preclinical effects of 2-substituted imidazoline
derivatives☆
Lorenzo Di Cesare Mannellia,⁎, Carla Ghelardinia, Laura Michelia, Fabio Del Bellob,
Mario Giannellab, Alessandro Piergentilib, Maria Piginib, Wilma Quagliab
a Department of Neuroscience, Psychology, Drug Research and Child Health - Neurofarba - Pharmacology and Toxicology Section, University of Florence,
Viale Pieraccini 6, 50039 Firenze, Italy
b School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy
A R T I C L E I N F O
Chemical compounds studied in this article:
(S)-(-)-1 (PubChem CID 10333157)
2 (PubChem CID 11265631)
3 (PubChem CID 11211035)
4 (PubChem CID 44549156)
5 (PubChem CID 23622576)
Keywords:
Imidazoline
Mixed 5HT1A/α2agonists
CCI
Neuropathy
Chronic pain
Gabapentin
A B S T R A C T
Neuropathic pain affects millions of people causing disability and impairing quality of life. Commonly used
analgesics are generally characterized by limited therapeutic outcomes. The serotonin 5‐HT1A receptor and the
α2 adrenergic receptors are involved in central nociceptive mechanisms with a pivotal role in the inhibitory
descending pain pathway. Since their stimulation may modulate the nervous signaling altered by neuropathies,
the purpose of the present research is the study of the combined activation of 5‐HT1A and α2 receptors by
rationally designed imidazoline ligands ((S)-(-)-1 and 2–5) in a rat model of neuropathic pain (chronic
constriction injury - CCI). On day 14 after nerve damage, the acute administration per os (p.o.) of low doses of
(S)-(-)-1 (0.1–1 mg/kg) was able to significantly increase the pain threshold to mechanical noxious stimuli for
more than 1 h. (S)-(-)-1 efficacy was confirmed by the decrease of spontaneous pain evaluated as hind limb
weight bearing alterations. The clinically-used compound gabapentin (100 mg/kg p.o.) induced a pain relieving
effect similar to (S)-(-)-1 administered at 100 fold lower dose. In the same model, the selected analogues,
compounds 2–5 (1 mg/kg p.o.) were effective 30 min after administration. In particular, 5 fully reverted the
CCI-induced hypersensitivity. The pain relieving activity of 5 was significantly prevented by the selective 5-HT1A
receptor antagonist WAY 100635 (1 mg/kg intraperitoneally, i.p.) and, at a lesser extent, by the α2 antagonist
yohimbine (3 mg/kg i.p.). A novel pharmacodynamic approach to the treatment of neuropathic pain is
presented.
1. Introduction
The treatment of neuropathic pain is heavily hampered by the
pathological changes of the pain pathways that characterized this
condition (Garland, 2012). The use of opioids, fully active against
nociceptive pain, is unsatisfactory in neuropathic patients (McNicol
et al., 2013; Sun et al., 2017), in addition their long-term use is related
to the development of pharmacodynamic tolerance (Ballantyne and
Shin, 2008; Dumas and Pollack, 2008). Non-analgesic drugs, like anti-
depressants or anti-epileptics, are currently used despite the partial
efficacy and the significant side-effects (Hurley et al., 2013).
The pathological aspects of neuropathic pain involve a maladaptive
response of the nervous system characterized by peripheral and central
sensitization and spinal disinhibition. Disruption of the balance of
descending modulatory circuits to favour facilitation may promote and
maintain chronic pain (Von Hehn et al., 2012; Ossipov et al., 2010; Di
Cesare Mannelli et al., 2015a). This scenario is consistent with the
clinical success of drugs that enhance spinal monoaminergic activity,
such as serotonin/norepinephrine reuptake inhibitors (SNRIs), in the
treatment of chronic pain states. Among the serotonin receptors, the 5‐
HT1A receptor has been one of the first to be pharmacologically
characterized (Fargin et al., 1988, 1989). It is expressed in the raphe
nucleus and in several postsynaptic areas involved in central nocicep-
tive mechanisms (Kalipatnapu and Chattopadhyay, 2007). Full and
partial 5-HT1A receptor agonists have shown to be beneficial in pain
treatments (Nadeson and Goodchild, 2002) arousing great interest as
future therapeutic agents (Muthuraman et al., 2014; Panczyk et al.,
2015).
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On the other side, among the receptors recognized by noradrena-
line, α2 receptor activation decrease the intracellular adenylyl-cyclase
activity through Gi or directly modify the activity of ion channels
(Summers and McMartin, 1993; Giovannoni et al., 2009). The three
subtypes (α2A, α2B and α2C) are involved in different physiological
functions and their pharmacological stimulation elicits anti-hyperalge-
sic effects; the prototype agonist clonidine is currently in clinical use in
spite of a not optimal safety profile (Szczudlik et al., 2014). Besides
clonidine, other 2-substituted imidazolines are used in human or
veterinary pain treatment (Giovannoni et al., 2009). Moreover, the
multiplicity of the effects produced by imidazoline compounds high-
lights the wide bioversatility of this scaffold (Dardonville and Rozas,
2004; Krasavin, 2015).
It has been demonstrated that the (S)-(-) enantiomer of biphenyline
(1, Fig. 1), described as α2 receptor (Gentili et al., 2002) and 5-HT1A
receptor (Del Bello et al., 2016) agonist, behaved as a potent and long-
lasting antinociceptive agent in algesiometric paradigms (Gentili et al.,
2002).
Considering the important role played by both 5-HT1A and α2
receptors in nociception (Colpaert, 2006; Deseure et al., 2007; Di
Cesare Mannelli et al., 2015a), in the present research we examined the
pain relieving effect of (S)-(-)-1 in the rat model of peripheral
mononeuropathy induced by chronic constriction injury (CCI) of the
sciatic nerve. Moreover, to obtain more information about the role of 5-
HT1A and α2 receptors in the neuropathic pain relieving effect of (S)-
(-)-1, and eventually improve its pharmacological efficacy, the structu-
rally analogues 2–5 (Fig. 1) have been rationally selected to be tested
in the same rat model of peripheral neuropathy.
2. Materials and methods
2.1. Drugs
Compound (S)-(-)-1 ((S)-2-(1-([1,1′-biphenyl]-2-yloxy)ethyl)-4,5-
dihydro-1H-imidazole) was obtained treating methyl (S)-2-([1,1′-bi-
phenyl]-2-yloxy)propanoate with ethylenediamine and trimethyl alu-
minium at 40 °C in toluene (Gentili et al., 2002).
Compounds 2 (3-(2-(1-(4,5-dihydro-1H-imidazol-2-yl)ethoxy)phe-
nyl)pyridine) and 3 (2-(1-((3′-fluoro-[1,1′-biphenyl]-2-yl)oxy)ethyl)-
4,5-dihydro-1H-imidazole) were obtained treating 2-(2-(pyridin-3-yl)
phenoxy)propanenitrile or 2-((3′-fluoro-[1,1′-biphenyl]-2-yl)oxy)pro-
panenitrile, respectively, with ethylenediamine in the presence of
sodium methoxide (Gentili et al., 2004).
Compounds 4 (2-(1-(2-cyclopropylphenoxy)ethyl)-4,5-dihydro-1H-
imidazole) and 5 (2-(1-(2-cyclohexylphenoxy)ethyl)-4,5-dihydro-1H-
imidazole) were obtained treating methyl 2-(2-cyclopropylphenoxy)
propanoate or methyl 2-(2-cyclohexylphenoxy)propanoate, respec-
tively, with ethylenediamine and trimethyl aluminium at 110 °C in
toluene (Cardinaletti et al., 2009; Gentili et al., 2008).
2.2. Animals
Male Sprague-Dawley rats (Envigo, Varese, Italy) weighing approxi-
mately 200–250 g were used. Animals were housed in CeSAL (Centro
Stabulazione Animali da Laboratorio, University of Florence) and used
at least 1 week after their arrival. Four rats were housed per cage (size
26 × 41 cm); animals were fed a standard laboratory diet and tap water
ad libitum, and kept at 23 ± 1 °C with a 12 h light/dark cycle, light at
7 a.m. All animal manipulations were carried out according to the
Directive 2010/63/EU of the European parliament and of the
European Union council (22 September 2010) on the protection of
animals used for scientific purposes. The ethical policy of the
University of Florence complies with the Guide for the Care and Use
of Laboratory Animals of the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996; University of Florence assurance
number: A5278-01). Formal approval to conduct the experiments
described was obtained from the Animal Subjects Review Board of
the University of Florence. Experiments involving animals have been
reported according to ARRIVE guidelines (McGrath and Lilley, 2015).
All efforts were made to minimize animal suffering and to reduce the
number of animals used.
2.3. CCI-induced neuropathic pain model
Neuropathy was induced according to the procedure described by
Bennett and Xie (1988). Briefly, rats were anaesthetized with 2%
isoflurane. Under aseptic conditions, the right (ipsilateral) common
sciatic nerve was exposed at the level of the middle thigh by blunt
dissection. Proximal to the trifurcation, the nerve was carefully freed
from the surrounding connective tissue, and four chromic cat gut
ligatures (4-0, Ethicon, Norderstedt, Germany) were tied loosely
around the nerve with about a 1 mm spacing between ligatures. After
hemostasis was confirmed, the incision was closed in layers. The
animals were allowed to recover from surgery and then housed one
per cage with free access to water and standard laboratory chow.
Another group of rats was subjected to sham surgery in which the
sciatic nerve was only exposed but not ligated.
2.4. Pharmacological treatments
Compounds (S)-(-)-1 (0.1 and 1 mg/kg), 2–5 (1 mg/kg) and
gabapentin (100 mg/kg) were suspended in 1% carboxymethyl cellu-
lose and administered per os (p.o.). WAY 100635 (1 mg/kg) and
yohimbine (3 mg/kg) were dissolved in saline solution and injected
intraperitoneally (i.p.) 15 min before the administration of compound
5. The dosages of (S)-(-)-1 were chosen on the basis of the already
evaluated antinociceptive ED50 after subcutaneous administration
(Gentili et al., 2002) and opportunely modified for the p.o. treatment.
The doses of gabapentin, WAY 100635 and yohimbine were chosen on
the basis of previously published results (Di Cesare Mannelli et al.,
2015; Wang et al., 2013; Vergelli et al., 2015).
2.5. Paw-pressure test
The nociceptive threshold in the rat was determined with an
analgesiometer (Ugo Basile, Varese, Italy), according to the method
described by Leighton et al. (1988). Briefly, constantly increasing
pressure was applied to a small area of the dorsal surface of the hind
paw using a blunt conical mechanical probe. Mechanical pressure was
increased until vocalization or a withdrawal reflex occurred while rats
were lightly restrained. Vocalization or withdrawal reflex thresholds
were expressed in grams. Rats scoring below 40 g or over 75 g during
the test before drug administration were rejected (25%). The pain
threshold was evaluated before and 15, 30, 45, 60 and 90 min after
compound administration.
2.6. Incapacitance test
Weight-bearing changes were measured using an incapacitance
apparatus (Linton Instrumentation, Norfolk, UK) to detect changes in
postural equilibrium after a hind limb injury (Bove et al., 2003). Rats
were trained to stand on their hind paws in a box with an inclined plane
Fig. 1. Chemical structures of 1–5.
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(65° from horizontal). This box was placed above the incapacitance
apparatus. This allowed us to independently measure the weight that
the animal applied on each hind limb. The value reported for each
animal was the mean of 5 consecutive measurements. In the absence of
hind limb injury, rats applied an equal weight on both hind limbs,
indicating a postural equilibrium, whereas an unequal distribution of
the weight on hind limbs indicated a monolateral decreased pain
threshold. Data are expressed as the difference between the weight
applied to the limb contralateral to the injury and the weight applied to
the ipsilateral one (Δ Weight).
2.7. Statistical analysis
Behavioral measurements were performed on 6 rats for each
treatment carried out in 2 different experimental sets. Results were
expressed as means ± S.E.M. and the analysis of variance was
performed by Two-Way ANOVA. A Bonferroni's significant difference
procedure was used as post-hoc comparison. All assessments were
made by researchers blinded to cell or rat treatments. Data were
analyzed using the ‘‘Origin 8.1” software (OriginLab, Northampton,
USA).
3. Results
The pain relieving effects of the compounds were evaluated in rats
underwent CCI of the sciatic nerve. This rat model of mononeuropathy
provokes a painful syndrome beginning about 3 days after nerve
ligation and plateauing between 7 and 30 days (Pacini et al., 2010;
Di Cesare Mannelli et al., 2014). Fourteen days after injury, the
response to a noxious mechanical stimulus was measured by the Paw
pressure test. In the CCI + vehicle group the weight tolerated on the
ipsilateral paw decreased to 45.3 ± 2.1 g in comparison to 67.3 ± 2.1
g of control animals (sham + vehicle) (Fig. 2). (S)-(-)-1 (0.1 and 1 mg/
kg p.o.) was able to reduce the hypersensitivity induced by the loose
ligation of the sciatic nerve. The anti-hyperalgesic activity took effect
15 min after administration. (S)-(-)-1 (1 mg/kg, 30 min) showed an
anti-hyperalgesic efficacy of 56%, considering as 100% the complete
reversion of pain till the threshold of control animals. The effect was
still statistically significant 60 min after injection and vanished at
90 min (Fig. 2). The response of the contralateral paw was unaltered
(data not shown) suggesting the lack of analgesic effects. Gabapentin
was used as a reference compound since its relevant clinical use in
neuropathic patients (Szczudlik et al., 2014). The common and
accepted rat dosage of 100 mg/kg p.o. (Di Cesare Mannelli et al.,
2015) was active from 15 to 45 min after treatment inducing a relief
slightly higher (74% of anti-hyperalgesic efficacy) than (S)-(-)-1
administered at 100 fold lower dose (1 mg/kg) (Fig. 2).
As shown in Fig. 3, monolateral pain was also able to induce hind
limb weight bearing alterations (Incapacitance test). The difference
between the weight burdened on the contralateral and the ipsilateral
paw increased in CCI + vehicle (55.3 ± 4.2 g) in comparison to sham +
vehicle (7.3 ± 2.1 g). (S)-(-)-1 (1.0 mg/kg) significantly reduced the
hind limb weight bearing alterations in comparison to CCI + vehicle.
The effect started 15 min after administration and vanished at 60 min.
Fig. 2. Effect of acute administration of (S)-(-)-1 in comparison to gabapentin on CCI-
induced mechanical hypersensitivity. Peripheral neuropathy was induced by CCI of the
right sciatic nerve (ipsilateral); (S)-(-)-1 (0.1–1.0 mg/kg) was acutely administered p.o.
on day 14 after surgery. The Paw pressure test was used to measure the sensitivity to a
mechanical stimulus 0, 15, 30, 45, 60 and 90 min after compound administration.
Gabapentin (100 mg/kg, p.o.) was used as reference compound; sham animals were
treated with vehicle. Each value is the mean ± S.E.M. of 6 rats per group, performed in 2
different experimental sets. **P < 0.01 vs sham + vehicle; ^P < 0.05 and ^^P < 0.01 vs
CCI + vehicle.
Fig. 3. Effect of acute administration of (S)-(-)-1 in comparison to gabapentin on CCI-
induced hyperalgesia. Peripheral neuropathy was induced by CCI of the right sciatic
nerve (ipsilateral); (S)-(-)-1 (0.1 − 1 mg/kg) was acutely administered p.o. on day 14
after surgery. Incapacitance test was used to measure postural unbalance related to pain
0, 15, 30, 45, 60 and 90 min after compound administration. Gabapentin (100 mg/kg,
p.o.) was used as reference drug and sham animals were treated with vehicle. Data are
expressed as the difference between the weight applied to the limb contralateral to the
injury and the weight applied to the ipsilateral one (ΔWeight). Each value is the mean ±
S.E.M. of 6 rats per group, performed in 2 different experimental sets. **P < 0.01 vs sham
+ vehicle; ^P < 0.05 and ^^P < 0.01 vs CCI + vehicle.
Fig. 4. Effect of acute administration of compounds 2–5 in comparison to (S)-(-)-1 on
CCI-induced mechanical hypersensitivity. Peripheral neuropathy was induced by CCI of
the right sciatic nerve (ipsilateral), compounds were acutely administered p.o. (1.0 mg/
kg) on day 14 after surgery. The Paw pressure test was used to measure the sensitivity to
a mechanical stimulus 0, 15, 30, 45, 60 and 90 min after compound administration.
Sham animals were treated with vehicle. Each value is the mean ± S.E.M. of 6 rats per
group, performed in 2 different experimental sets. **P < 0.01 vs sham + vehicle; ^P <
0.05 and ^^P < 0.01 vs CCI + vehicle.
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A comparable effect was induced by the acute administration of
100 mg/kg gabapentin.
The imidazolines 2–5 were also effective in reducing the hyper-
sensitivity induced by the loose ligation of the sciatic nerve 30 min after
a single administration p.o. of 1 mg/kg. The percentages of anti-
hyperalgesic efficacy (30 min) of 2, 3, and 4 are 37.5%, 52.5%, and
35%, respectively; whereas 5 reaches 95% (Fig. 4). The pain killer effect
of 5 is long lasting in comparison to 2, 3 and 4 and the efficacy is
higher than (S)-(-)-1.
The co-administration of 5 with WAY 100635 (1 mg/kg i.p. 15 min
before 5) greatly reduced the pain relieving effect. In Fig. 5 (panel a), a
full reversion of 5 activity is shown with the exception of a break-
through at 30 min. The blocking effect induced by yohimbine (3 mg/kg
i.p. 15 min before 5) is significant 15 and 30 min after treatment even
if lesser in efficacy as well as duration (Fig. 5, panel b). The combined
administration of both the antagonists WAY 100635 (1 mg/kg i.p.) and
yohimbine (3 mg/kg i.p.), 15 min before 5, completely prevented the
pain relieving effect of compound 5 (Fig. 5, panel c).
4. Discussion
The descending pain modulatory system originates in the midbrain
(periaqueductal gray) and brainstem (rostroventromedial medulla) and
projects to the spinal cord dorsal horn, powerfully influencing the
modulation of nociceptive information transmitted from the periphery
to the brain (Von Hehn et al., 2012). The role of noradrenaline in this
system appears to be predominantly inhibitory, while the role of
serotonin appears to be bidirectional, mediating inhibitory as well as
excitatory effects (Ossipov et al., 2010). The increased activity of the
descending noradrenergic system and high extracellular levels of spinal
noradrenaline has been linked to antinociceptive/antiallodynic/anti-
hyperalgesic effects in acute and neuropathic pain (Di Cesare Mannelli
et al., 2015a). The 5‐HT1A receptor is expressed by all serotoninergic
neurons (as autoreceptors) and by many non serotoninergic neurons
(as heteroreceptors) in pain-related areas of the brain (Kalipatnapu
and Chattopadhyay, 2007). As already mentioned, 5-HT1A receptor
agonists have shown to produce efficacious antinociceptive effect in rats
Fig. 5. Evaluation of the 5-HT1A receptor and α2-adrenoceptor involvement in the pain relieving activity of compound 5. Peripheral neuropathy was induced by CCI of the right sciatic
nerve (ipsilateral). The Paw pressure test was performed on day 14 after surgery. 5 was acutely administered p.o. (1.0 mg/kg), WAY 100635 (1 mg/kg) and yohimbine (3 mg/kg) were
administered i.p. 15 min before. Sham animals were treated with vehicle. Each value is the mean ± S.E.M. of 6 rats per group, performed in 2 different experimental sets. Data of CCI +
vehicle groups are different (P < 0.01) vs sham + vehicle; ^P < 0.05 and ^^P < 0.01 vs CCI + vehicle; °°P < 0.01 vs CCI + 5 treated animals.
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(Nadeson and Goodchild, 2002). In particular, the 5‐HT1A agonist
F13640 provided the first evidence that the activation of this receptor
produces analgesia in a model of trigeminal neuropathic pain. It is
characterized by long-term analgesia in rodent models of peripheral
neuropathic pain and anti-allodynic action in spinal cord injured rat
(Colpaert et al., 2002; Deseure et al., 2002). As regards the α2
adrenergic receptor, the α2A, α2B and α2C subtypes have been identified
as potential contributors to nociceptive modulation being located in
key nodes of the nociceptive system. In the spinal cord, the α2 receptor
stimulation induces analgesia by post-synaptic hyperpolarization and
presynaptic inhibition of the excitatory transmission (Di Cesare
Mannelli et al., 2015a).
The double-face profile of the tested imidazoline compounds allows
the simultaneous modulation of neurotransmitter signals of great
relevance in pain mechanism. In particular, the efficacy of the 5-
HT1A receptor and α2 receptor agonist (S)-(-)-1 in reducing the
hypersensitivity and the hind limb weight bearing alterations induced
by the loose ligation of the sciatic nerve allows us to hypothesize the
involvement of both the receptor systems in its anti-neuropathic
activity.
The experiments performed with the selected imidazolines 2–5
provided further information about the role played by both 5-HT1A and
α2 receptors. The compounds have been selected considering their
good but different affinities for 5-HT1A receptor and similar agonist
activities at α2C subtype. They all behave as agonists at α2A subtype,
except for compound 4, which acts as an antagonist (Table 1). Based on
the observation that α2A subtype has been demonstrated to be critical
for the pain relieving actions of α2 receptor agonists in a mouse model
of neuropathic pain (Malmberg et al., 2001), this last compound might
confirm such a finding from a pharmacological point of view. Derivative
5, showing the highest affinity for 5-HT1A receptor and agonist activity
at all the α2 receptor subtypes, is the most effective compound in
reducing mechanical hypersensitivity. Compared to 5, the lower
efficacy of (S)-(-)-1, 2 and 3 in in vivo studies might be attributed to
their lower affinity for 5-HT1A receptor (Table 1). Though derivative 4
is characterized by 5-HT1A receptor affinity similar to that of 5
(Table 1), it also proved to be less effective in reducing the neuropathic
pain. This behaviour might result from its α2A antagonist profile,
supporting the finding that α2A receptor subtype is essential for the
anti-neuropathic effects mediated by α2 receptor agonists (Malmberg
et al., 2001). The comparable anti-neuropathic efficacy of the α2A
antagonist 4 and the α2A agonist 2 might be due to the significantly
higher affinity and agonist activity for 5-HT1A receptor of 4 with
respect to 2. The experiments performed with derivative 5 in the
presence of the 5-HT1A receptor antagonist WAY 100135 and the α2
receptor antagonist yohimbine confirm the relevance of the positive
modulation of both serotoninergic and adrenergic system in the
pharmacodynamic mechanism of such a compound. Therefore, the
double 5-HT1A/α2 agonist profile of the studied imidazoline derivatives
can produce a fruitful modulation of the descending antinociceptive
pathway. Moreover, the observation that yohimbine reduces the pain
relieving effect at lesser extent than WAY 100635 suggests a predomi-
nance of the 5-HT1A component.
5. Conclusion
In conclusion, the present study (i) highlights that the bioversatile
2-imidazoline substituted scaffold might be a valuable structure in the
building of novel anti-neuropathic agents. (ii) Noteworthy, the multi-
functional agent (S)-(-)-1 is able to reduce neuropathic pain at the dose
of 1.0 mg/kg, being 100 fold more potent than the clinically used
gabapentin. (iii) Moreover, compounds 2–5 show different efficacies
and potencies after per os treatment of CCI rats, providing useful
information on the role played by the 5-HT1A and α2 receptors in their
neuropathic pain relieving effect. In particular 5, showing the highest
affinity for the 5-HT1A receptor and agonist activity at all the α2
receptor subtypes, is the most effective compound in reducing mechan-
ical hypersensitivity through a mechanism significantly inhibited by the
pharmacological blockade of 5-HT1A or α2 receptors. Therefore, the
combined 5-HT1A/α2 receptors activation might be considered a
promising pharmacodynamic approach to the treatment of neuropathic
pain.
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